Paternoster Gianluca, De Rosa Silvia, Bertini Pietro, Innelli Pasquale, Vignale Rosaria, Tripodi Vincenzo Francesco, Buscaglia Giuseppe, Vadalà Mariacristina, Rossi Michele, Arena Antonio, Demartini Andrea, Tripepi Giovanni, Abelardo Domenico, Pittella Giuseppe, Di Fazio Aldo, Scolletta Sabino, Guarracino Fabio, de Arroyabe Blanca Martinez Lopez
Cardiovascular Anesthesia and ICU, San Carlo Hospital, 85100 Potenza, Italy.
Department of Anesthesia and Intensive Care Unit, San Bortolo Hospital, 36100 Vicenza, Italy.
Rev Cardiovasc Med. 2022 Sep 14;23(9):314. doi: 10.31083/j.rcm2309314. eCollection 2022 Sep.
The combination of surgery, bacterial spread-out, and artificial cardiopulmonary bypass surfaces results in a release of key inflammatory mediators leading to an overshooting systemic hyper-inflammatory condition frequently associated with compromised hemodynamics and organ dysfunction. A promising approach could be extracorporeal blood purification therapies in combination with IgM enriched immunoglobulin. This approach might perform a balanced control of both hyper and hypo-inflammatory phases as an immune-modulating intervention.
We performed a retrospective observational study of patients with proven infection after cardiac surgery between January 2020 and December 2021. Patients were divided into two groups: (1) the first group (Control Group) followed a standard care approach as recommended by the Surviving Sepsis Campaign Guidelines; The second group (Active Group) underwent extracorporeal blood purification therapy (EBPT) in combination with intravenous administration of IgM enriched immunoglobulin 5 mL/kg die for at least three consecutive days, in conjunction with the standard approach (SSC Guidelines). In addition, ventriculo-arterial (V/A) coupling, Interleukin 6 (IL-6), Endotoxin Activity Assay (EAA), Procalcitonin, White Blood Cells (WBC) counts, Sequential Organ Failure Assessment (SOFA) Score and Inotropic Score were assessed in both two groups at different time points.
Fifty-four patients were recruited; 25 were in the Control Group, while 29 participants were in the Active Group. SOFA score significantly improved from baseline [12 (9-16)] until at [8 (3-13)] in the active group; it was associated with a median EAA reduction from 1.03 (0.39-1.20) at to 0.41 (0.2-0.9) at in the active group compared with control group 0.70 (0.50-1.00) at to 0.70 (0.50-1.00) at ( 0.001). V/A coupling tended to be lower in patients of the active arm ranging from 1.9 (1.2-2.7) at to 0.8 (0.8-2.2) at than in those of the control arm ranging from 2.1 (1.4-2.2) at T0 to 1.75 (1.45-2.1) at ( = 0.099). The hemodynamic improvement over time was associated with evident but no significant decrease in inotropic score in the active group compared with the control group. Changes in EAA value from to were directly and significantly related (r = 0.39, = 0.006) to those of V/A coupling.
EBPT, in combination with IgM enriched immunoglobulin, was associated with a mitigated postoperative response of key cytokines with a significant decrease in IL-6, Procalcitonin, and EAA and was associated with improvement of clinical and metabolic parameters.
手术、细菌播散和人工心肺旁路表面的联合作用导致关键炎症介质的释放,进而引发全身性过度炎症反应,常伴有血流动力学受损和器官功能障碍。一种有前景的方法可能是体外血液净化疗法联合富含IgM的免疫球蛋白。这种方法可能作为一种免疫调节干预措施,对炎症反应的亢进期和减退期进行平衡控制。
我们对2020年1月至2021年12月期间心脏手术后确诊感染的患者进行了一项回顾性观察研究。患者分为两组:(1)第一组(对照组)遵循《拯救脓毒症运动指南》推荐的标准治疗方法;第二组(治疗组)在遵循标准方法(SSC指南)的同时,接受体外血液净化疗法(EBPT)联合静脉注射富含IgM的免疫球蛋白,剂量为5 mL/kg,连续至少三天。此外,在不同时间点对两组患者的心室-动脉(V/A)耦合、白细胞介素6(IL-6)、内毒素活性测定(EAA)、降钙素原、白细胞(WBC)计数、序贯器官衰竭评估(SOFA)评分和血管活性评分进行评估。
共招募了54例患者;25例在对照组,29例在治疗组。治疗组的SOFA评分从基线时的[12(9 - 16)]显著改善至[8(3 - 13)];与对照组相比,治疗组的EAA中位数从基线时的1.03(0.39 - 1.20)降至[具体时间点]时的0.41(0.2 - 0.9),而对照组在相应时间点从0.70(0.50 - 1.00)降至0.70(0.50 - 1.00)(P < 0.001)。治疗组患者的V/A耦合在[具体时间点1]时为1.9(1.2 - 2.7),至[具体时间点2]时为0.8(0.8 - 2.2),倾向于低于对照组,对照组在T0时为2.1(1.4 - 2.2),至[具体时间点2]时为1.75(1.45 - 2.1)(P = 0.099)。与对照组相比,治疗组随时间的血流动力学改善与血管活性评分的明显但无显著下降相关。从[具体时间点1]到[具体时间点2],EAA值的变化与V/A耦合的变化直接且显著相关(r = 0.39,P = 0.00)。
EBPT联合富含IgM的免疫球蛋白与关键细胞因子术后反应减轻相关,IL - 6、降钙素原和EAA显著降低,并与临床和代谢参数的改善相关。